Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANTAL: Chemo-radiotherapy vs Radiotherapy in Salivary/Nasal Tumors
NCT02998385Phase 3Active, not recruiting
- Sponsor
- GORTEC
- Start
- Jan 2017
- Primary completion
- Feb 2030
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Cisplatin micelle injection (HA132) in salivary gland carcinoma (SGC) and sinonasal carcinoma (2 arms), sponsored by GORTEC. Primary endpoint: Progression-Free Survival at 62 months. Started Jan 2017; status: active, not recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
salivary gland carcinoma (SGC)sinonasal carcinoma
Beyond the preview
Go deeper on NCT02998385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998385.